Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates.

[1]  L. Dogliotti,et al.  Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. , 2000, The Journal of urology.

[2]  T. Martin,et al.  Therapeutic approaches to bone diseases. , 2000, Science.

[3]  S. Teitelbaum,et al.  Bone resorption by osteoclasts. , 2000, Science.

[4]  M. Wilhelm,et al.  Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma , 2000 .

[5]  L. Chung,et al.  LNCaP progression model of human prostate cancer: Androgen‐independence and osseous metastasis , 2000, The Prostate.

[6]  Y. Horiguchi,et al.  Serum interleukin 6 as a prognostic factor in patients with prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  F. Orr,et al.  Pathophysiologic interactions in skeletal metastasis , 2000, Cancer.

[8]  W. Oh.  Chemotherapy for patients with advanced prostate carcinoma , 2000, Cancer.

[9]  G. van der Pluijm,et al.  Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton , 2000, Cancer.

[10]  P Delmas,et al.  Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. , 2000, Cancer research.

[11]  R. Rizzoli,et al.  Markers of bone turnover for the management of patients with bone metastases from prostate cancer , 2000, British Journal of Cancer.

[12]  Sundeep Khosla,et al.  The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  D. Ferguson,et al.  Progressive osteoporosis during androgen deprivation therapy for prostate cancer. , 2000, The Journal of urology.

[14]  D. Petrylak,et al.  Chemotherapy for advanced hormone refractory prostate cancer. , 1999, Urology.

[15]  R. Bataille,et al.  Zoledronate Is a Potent Inhibitor of Myeloma Cell Growth and Secretion of IL‐6 and MMP‐1 by the Tumoral Environment , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  P. Croucher,et al.  The pharmacology of bisphosphonates and new insights into their mechanisms of action , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  N. Koszewski,et al.  Vitamin D Receptor Interactions with the Rat Parathyroid Hormone Gene: Synergistic Effects Between Two Negative Vitamin D Response Elements , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  S. Cerutti,et al.  Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. , 1999, Clinical chemistry.

[19]  L. Chung,et al.  Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment , 1999, The Prostate.

[20]  G. Mundy,et al.  Systemic Administration of Acidic Fibroblast Growth Factor (FGF‐1) Prevents Bone Loss and Increases New Bone Formation in Ovariectomized Rats , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  C. Löwik,et al.  The Role of Geranylgeranylation in Bone Resorption and Its Suppression by Bisphosphonates in Fetal Bone Explants In Vitro: A Clue to the Mechanism of Action of Nitrogen‐Containing Bisphosphonates , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  D. Grignon,et al.  Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. , 1999, Cancer research.

[23]  T. Diamond,et al.  The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma , 1998, Cancer.

[24]  P. Kantoff,et al.  Management of hormone refractory prostate cancer: current standards and future prospects. , 1998, The Journal of urology.

[25]  G. Andriole,et al.  A phase I/II dose ranging study of DUROS (TM) (leuprolide) implantable therapeutic system in patients with advanced prostate cancer , 1998 .

[26]  M. Rogers,et al.  Nitrogen‐Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post‐Translational Prenylation of GTP‐Binding Proteins, Including Ras , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  A. Zwinderman,et al.  Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. , 1998, Bone.

[28]  C. Miyaura,et al.  Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. , 1998, Endocrinology.

[29]  T. Yoneda.  Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. , 1998, European journal of cancer.

[30]  T. Guise,et al.  Cancer and bone. , 1998, Endocrine reviews.

[31]  L. Dogliotti,et al.  Pamidronate administration improves the secondary hyperparathyroidism due to “Bone hunger syndrome” in a patient with osteoblastic metastases from prostate cancer , 1997, The Prostate.

[32]  S. Nilsson,et al.  The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. , 1997, Anticancer research.

[33]  L. Dogliotti,et al.  Comparison of Assay of Total and Bone-Specific Alkaline Phosphatase in the Assessment of Osteoblast Activity in Patients with Metastatic Bone Disease , 1997, Calcified Tissue International.

[34]  D. Goltzman.  Mechanisms of the development of osteoblastic metastases , 1997, Cancer.

[35]  R. Coleman.  Skeletal complications of malignancy , 1997, Cancer.

[36]  G. Mundy,et al.  Mechanisms of bone metastasis , 1997, Cancer.

[37]  S. Adami.  Bisphosphonates in prostate carcinoma , 1997, Cancer.

[38]  J. Kanis,et al.  Bone turnover and biochemical markers in malignancy , 1997, Cancer.

[39]  P. Delmas,et al.  Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. , 1997, Cancer research.

[40]  M. Koizumi,et al.  Correlation between bone metabolic markers and bone scan in prostatic cancer. , 1997, The Journal of urology.

[41]  S. Barni,et al.  Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumour patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2. , 1997, European journal of cancer.

[42]  J. Risteli,et al.  Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer. , 1997, British Journal of Cancer.

[43]  G. Hortobagyi,et al.  Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. , 1996, The New England journal of medicine.

[44]  J. Bonneterre,et al.  Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Zuxiong Chen,et al.  Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. , 1996, The Journal of urology.

[46]  H. Vloedgraven,et al.  Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. , 1996, The Journal of clinical investigation.

[47]  R. Eastell,et al.  Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. , 1996, Cancer treatment reviews.

[48]  G. Rodan,et al.  Bisphosphonates: mechanisms of action , 1998, Endocrine reviews.

[49]  L. Dogliotti,et al.  Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. , 1996, British Journal of Cancer.

[50]  R. Eastell,et al.  Metabolic effects of pamidronate in patients with metastatic bone disease. , 1996, British Journal of Cancer.

[51]  M. Kovacs,et al.  Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. , 1996, The New England journal of medicine.

[52]  A. Parfitt,et al.  Theoretical perspective: A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates , 1996 .

[53]  G. Mundy,et al.  Human amniotic tumor that induces new bone formation in vivo produces growth-regulatory activity in vitro for osteoblasts identified as an extended form of basic fibroblast growth factor. , 1996, Cancer research.

[54]  M. Stearns,et al.  Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. , 1996, Invasion & metastasis.

[55]  E. Engleman,et al.  Inhibition of antigen‐presenting cell function by alendronate in vitro , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[56]  J. Roberts,et al.  Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. , 1995, British journal of urology.

[57]  S. Manolagas,et al.  Role of cytokines in bone resorption. , 1995, Bone.

[58]  T. Diamond,et al.  Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer. , 1995, The Journal of urology.

[59]  L. Bonewald,et al.  The effects of cytokines and growth factors on osteoblastic cells. , 1995, Bone.

[60]  J. Kanis,et al.  Consequences of neoplasia induced bone-resorption and the use of clodronate (review). , 1994, International journal of oncology.

[61]  T. Ohishi,et al.  Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis. , 1994, British Journal of Cancer.

[62]  R. Coleman,et al.  High-dose intravenous pamidronate for metastatic bone pain. , 1994, British Journal of Cancer.

[63]  L. Bonewald,et al.  Effects of transforming growth factor β on bone nodule formation and expression of bone morphogenetic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type I collagen mRNA in long‐term cultures of fetal rat calvarial osteoblasts , 1994 .

[64]  K. Jaeggi,et al.  Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[65]  S. Rabbani,et al.  Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. , 1994, Cancer research.

[66]  L. Bonewald,et al.  Characterization and autoregulation of latent transforming growth factor beta (TGF beta) complexes in osteoblast-like cell lines. Production of a latent complex lacking the latent TGF beta-binding protein. , 1994, The Journal of biological chemistry.

[67]  T. Tammela,et al.  The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. , 1994, Annales chirurgiae et gynaecologiae.

[68]  S. Ralston,et al.  Pathogenesis and management of cancer associated hypercalcaemia. , 1994, Cancer surveys.

[69]  J. Kanis,et al.  Distinction between focally accelerated bone formation and osteomalacia in carcinoma of prostate metastasised to bone. , 1993, British journal of urology.

[70]  R. Vassilopoulou-sellin,et al.  Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center , 1993, Cancer.

[71]  L. Denis.  Prostate cancer. Primary hormonal treatment , 1993 .

[72]  N. Clarke,et al.  Osteoblast function and osteomalacia in metastatic prostate cancer. , 1993, European urology.

[73]  K. Kato,et al.  In vivo stimulation of endosteal bone formation by basic fibroblast growth factor in rats. , 1993, Growth factors.

[74]  M. Laakso,et al.  Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma , 1992, The Lancet.

[75]  A. Geldof,et al.  Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates. , 1992, The Journal of urology.

[76]  A. Mazar,et al.  Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. , 1992, The Journal of biological chemistry.

[77]  D. Dodwell.  Malignant bone resorption: cellular and biochemical mechanisms. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[78]  F. J. Johnson,et al.  Pathogenesis of vertebral crush fractures in men. , 1992, Age and ageing.

[79]  E. Bruera,et al.  A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. , 1992, Journal of pain and symptom management.

[80]  H. Fleisch.  Bisphosphonates , 2012, Drugs.

[81]  N. Clarke,et al.  Morphometric evidence for bone resorption and replacement in prostate cancer. , 1991, British journal of urology.

[82]  F. Singer.  Paget's Disease of Bone: Clinical Assessment, Present and Future Therapy , 1991 .

[83]  N. Clarke,et al.  Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study. , 1991, British Journal of Cancer.

[84]  J. Kanis,et al.  Treatment of Paget’s Disease with the New Bisphosphonates , 1991 .

[85]  M. Soloway.  The Importance of Prognostic Factors in Advanced Prostate Cancer , 1990, Cancer.

[86]  M. Harada,et al.  Effects of a new bisphosphonate (AHBuBP) on osteolysis induced by human prostate cancer cells in nude mice. , 1990, The Journal of urology.

[87]  S. Ralston,et al.  Cancer-Associated Hypercalcemia: Morbidity and Mortality: Clinical Experience in 126 Treated Patients , 1990 .

[88]  J. Cabranes,et al.  Hyperparathyroidism in metastases of prostatic carcinoma: a biochemical, hormonal and histomorphometric study. , 1990, European urology.

[89]  J. Reginster,et al.  PREVENTION OF POSTMENOPAUSAL BONE LOSS BY TILUDRONATE , 1989, The Lancet.

[90]  E. Canalis,et al.  Growth factors and the skeletal system , 1989, Journal of endocrinological investigation.

[91]  S. Ishikawa,et al.  Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. , 1989, The Journal of urology.

[92]  J. Smith,et al.  Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. , 1989, The Journal of urology.

[93]  M. Lippert,et al.  Treatment of painful prostatic bone metastases with oral etidronate disodium. , 1988, Urology.

[94]  M. Harada,et al.  Establishment of a model to evaluate inhibition of bone resorption induced by human prostate cancer cells in nude mice. , 1988, The Journal of urology.

[95]  M. Pollard,et al.  Effects of diphosphonate and X‐Rays on bone lesions induced in rats by prostate cancer cells , 1988, Cancer.

[96]  E. Canalis,et al.  Effects of basic fibroblast growth factor on bone formation in vitro. , 1988, The Journal of clinical investigation.

[97]  J. Coindre,et al.  Sclerotic bone metastases of prostatic origin and osteomalacia. Importance of a histomorphometry study. , 1987, Progress in clinical and biological research.

[98]  S. Matsui,et al.  Heparin binding affinity of rat prostatic growth factor in normal and cancerous prostates: partial purification and characterization of rat prostatic growth factor in the Dunning tumor. , 1987, Cancer research.

[99]  E. Canalis,et al.  Effects of endothelial cell growth factor on bone remodelling in vitro. , 1987, The Journal of clinical investigation.

[100]  S. Adami,et al.  Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. , 1985, The Journal of urology.

[101]  J. Kanis,et al.  Generalised increase in bone resorption in carcinoma of the prostate. , 1985, British journal of urology.

[102]  L. Melton,et al.  Risk factors for spinal osteoporosis in men. , 1983, The American journal of medicine.

[103]  S. Jacobs.  Spread of prostatic cancer to bone. , 1983, Urology.

[104]  M. Chapuy,et al.  Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia , 1983, Cancer.

[105]  R. Recker,et al.  Bone histomorphometry : techniques and interpretation , 1983 .

[106]  P. Walsh,et al.  The influence of hormonal therapy on survival of men with advanced prostatic cancer. , 1982, The Journal of urology.

[107]  F. Orr,et al.  Responses of normal and malignant cells to collagen, collagen-derived peptides and the C5-related tumor cell chemotactic peptide. , 1981, Cell differentiation.

[108]  D. Rowe,et al.  Collagen and collagen-derived fragments are chemotactic for tumor cells. , 1981, The Journal of clinical investigation.

[109]  G. Gordan.  Clinical Aspects of Metabolic Bone Disease , 1975 .